Ipsen Commercial Chief: Buying Clementia Will Bolster Rare Disease Franchise

Buying Canada-based Clementia is consistent with Ipsen’s strategy to acquire top assets in mid to late stages of development for specialty oncology, neuroscience or rare disease indications, chief commercial officer tells Scrip.

Handshake
Deal Could Transform Ipsen’s ultra-rare disease business • Source: Shutterstock

More from Deals

More from Business